Fust Matthew K's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Sep 30, 2025
- Accession no.
- 0001658247-25-000010
- Filed
- Sep 30, 2025
- Trade date
- Sep 26, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $716.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fust Matthew KCIK 0001397266 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | Common Stock | MOption exerciseAcquired | +10,000 | $1.91 | +$19,100 | 38,836 | Direct | |
| Sep 26, 2025 | Common Stock | SSaleDisposed | −16,000 | $44.75F2 | −$716,000 | 22,836 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 2,092 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $44.75 per share.
Referenced by the price of 1 transaction in Table I.